Bellus Health
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Bellus Health and buy or sell other stocks, options, and ETFs commission-free!About BLU
BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTA™, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death.
CEORoberto Bellini
CEORoberto Bellini
Employees—
Employees—
HeadquartersLaval, Québec
HeadquartersLaval, Québec
Founded1993
Founded1993
Employees—
Employees—
BLU Key Statistics
Market cap1.87B
Market cap1.87B
Price-Earnings ratio-20.45
Price-Earnings ratio-20.45
Dividend yield—
Dividend yield—
Average volume4.95M
Average volume4.95M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$14.76
52 Week high$14.76
52 Week low$6.38
52 Week low$6.38